Published Studies Related to Zosyn (Piperacillin / Tazobactam)
Piperacillin/tazobactam monotherapy versus piperacillin/tazobactam plus amikacin as initial empirical therapy for febrile neutropenia in children with acute leukemia. [2011.05]
The purpose of this study is to compare the efficacy and safety of piperacillin/tazobactam (PIP/TAZO) versus PIP/TAZO plus amikacin in febrile neutropenic children with acute leukemia (AL). Children with AL who had febrile neutropenic episodes were randomized to treatment with PIP/TAZO versus PIP/TAZO plus amikacin...
Microbiological equivalence of bacteriostatic and bactericidal activities of the sera from healthy volunteers receiving generic piperacillin/tazobactam (Pipertaz) and original piperacillin/tazobactam (Tazocin). [2011.02]
CONCLUSION: The sera from healthy volunteers receiving Pipertaz contain bacteriostatic and bactericidal activities not significantly different from those receiving Tazocin.
Piperacillin-tazobactam versus carbapenem therapy with and without amikacin as empirical treatment of febrile neutropenia in cancer patients: results of an open randomized trial at a university hospital. [2010.08]
OBJECTIVE: Empirical beta-lactam monotherapy has become the standard therapy in febrile neutropenia. The aim of this study was to compare the efficacy and safety of piperacillin-tazobactam versus carbapenem therapy with or without amikacin in adult patients with febrile neutropenia... CONCLUSIONS: The effect of empirical regimen of piperacillin-tazobactam regimen is equivalent to carbapenem in adult febrile neutropenic patients.
Piperacillin/tazobactam versus imipenem/cilastatin for severe diabetic foot infections: a prospective, randomized clinical trial in a university hospital. [2010.08]
In this prospective, randomized, open-label clinical trial, we compared the efficacy and safety of two antibiotic regimens for severe diabetic foot infections (DFI). Sixty-two in-patients with DFI received either piperacillin/tazobactam (Pip-Tazo, n = 30) (4.5 g intravenously every 8h) or imipenem/cilastatin (IMP, n = 32) (0.5 g intravenously every 6h)...
Low-dose beta-lactam plus amikacin in febrile neutropenia: cefepime vs. piperacillin/tazobactam, a randomized trial. [2010.04]
Patients with fever and granulocytopenia are at risk of developing severe infection. We performed a prospective, randomized trial to evaluate the efficacy of low-dose cefepime plus amikacin (C-A) compared to low-dose piperacillin/tazobactam plus amikacin (PT-A)...
Clinical Trials Related to Zosyn (Piperacillin / Tazobactam)
Continuous Infusion Piperacillin-tazobactam for the Treatment of Cystic Fibrosis [Recruiting]
Cystic fibrosis is an inherited disorder leading to chronic pulmonary inflammation and
infection. A majority of people with cystic fibrosis have large quantities of bacteria
residing in their lungs. One of the most common and harmful bacteria is called Pseudomonas
Patients with cystic fibrosis require frequent therapy with intravenous (I. V.) antibiotics
to treat lung infections thought to be caused by Pseudomonas aeruginosa. One of the
antibiotics frequently used to treat this bacteria is piperacillin-tazobactam.
Piperacillin-tazobactam is thought to be the most effective when there is a constant level
of drug in the body. The standard way to administer piperacillin-tazobactam is to give
several grams 4 times each day as a 30 minute infusion. An alternative way to give
piperacillin-tazobactam is by a continuous infusion; a continuous infusion will make it more
likely that drug will remain at a constant level in the body. The objective of this study is
to determine if administering piperacillin-tazobactam as a continuous infusion is more
effective at treating people having a pulmonary exacerbation of cystic fibrosis than a
standard 30 minute infusion, 4 times a day.
Piperacillin-Tazobactam Continuous Versus Intermittent Infusion for Pseudomonas Aeruginosa [Recruiting]
The main objective is to verify that the administration of piperacillin / tazobactam
administered by continuous infusion to treat complicated infections or with known or
suspected nosocomial isolation of Pseudomonas aeruginosa is superior in efficacy to a 30%
higher dose administered in conventional short infusion.
The secondary objectives were compared between the following variables:
- Microbiological response at 3 days of starting treatment
- Time to microbiological cure
- Clinical response at 3 days of starting treatment
- Time to achieve defervescence
- To examine the relationship between pharmacokinetic variables and parameters of
efficacy and safety
- To test the hypothesis that continuous infusion maintains adequate plasma drug levels
compared with levels achieved with intermittent administration.
- Cost-effectiveness analysis
- Occurrence of adverse effects
To this end, we designed a multicenter, randomized, controlled, double blind, comparing both
forms of administration in patients with complicated or nosocomial infection with or without
isolation of Pseudomonas aeruginosa.
Patients who are candidates for inclusion are classified according to APACHE II and to have
or not isolation of Pseudomonas aeruginosa. Subsequently be randomized to receive
piperacillin-tazobactam by continuous infusion or short. Primary endpoint was measured as
the ultimate effectiveness of treatment and other variables such as high efficiency, safety,
pharmacokinetic and pharmacoeconomic.
Pharmacokinetics and Safety of Piperacillin-tazobactam in Neonates [Recruiting]
This is a phase I open label multi-dose study to investigate the pharmacokinetics and safety
of piperacillin-tazobactam in infants < 61 days of age with suspected sepsis. There will be
four cohorts of 8 infants each:
1. < 32 weeks gestational age and < 14 days postnatal age
2. < 32 weeks gestational age and >=14 days postnatatal age
3. >=32 weeks gestational age and < 14 days postnatal age
4. >=32 weeks gestational age and >=14 days postnatal age. The study requires
administration of 6 doses of study drug along with other antimicrobials per standard of
care followed by 1 week of safety monitoring. Four 200 ÁL pK samples will be obtained
at steady state. The risks are reasonable vs. the benefits and have been minimized
appropriately. There may be benefit to the subjects (administration of broad spectrum
empirical antimicrobial therapy), and information from the study may benefit a large
number of other infants in whom the drug is currently being administered despite the
lack of PK data in this population.
Study Comparing Piperacillin-Tazobactam Versus Piperacillin-Tazobactam Plus Glycopeptide in Neutropenic Patients [Recruiting]
The aim of this study is to compare the efficacy and tolerance of piperacillin-tazobactam
versus piperacillin-tazobactam plus glycopeptide as initial empiric antibiotic treatment for
fever in neutropenic patients. Study of consecutive cohorts(2). First the patients will
be included in the monotherapy branch until completing the predicted number of cases. When
this happens, the Coordinating Center will communicate it to the participant centers and
from then the patients will be included in the combined therapy.
Study Evaluating Zosyn in Hospitalized Patients With Intra-Abdominal Infection [Completed]
A Phase IV, multicenter study of hospitalized patients with complicated intra-abdominal
Reports of Suspected Zosyn (Piperacillin / Tazobactam) Side Effects
Hepatic Function Abnormal (16),
Interstitial Lung Disease (14),
Drug Interaction (11),
Renal Failure Acute (11),
Liver Disorder (10),
Renal Impairment (9),
Alopecia (9), more >>